Randal J.  Kirk net worth and biography

Randal Kirk Biography and Net Worth

Director of Precigen
Mr. Kirk has served as Executive Chairman of the Board since January 2020 and previously served as Chairman of the Board from February 2008 until January 2020 and as our CEO from April 2009 until January 2020. Mr. Kirk provides a wealth of strategic, operational, and management experience. Mr. Kirk currently serves as the Senior Managing Director and CEO of Third Security, LLC, an investment management firm founded by Mr. Kirk in March 1999. Additionally, Mr. Kirk founded and became Chairman of the Board of New River Pharmaceuticals Inc. (a biopharmaceutical company previously traded on Nasdaq prior to its acquisition by Shire plc in 2007) in 1996, and was President and CEO between October 2001 and April 2007.

Since May 2015, Mr. Kirk has served as a member of the board of directors of the Edward Via College of Osteopathic Medicine. Previously, Mr. Kirk served as a member of the board of directors of Scios, Inc. (previously traded on Nasdaq prior to its acquisition by Johnson & Johnson) between February 2000 and May 2002, as a member of the board of directors of Halozyme Therapeutics, Inc. (Nasdaq: HALO), a clinical stage biotechnology company, from May 2007 to May 2018, as a member of the board of directors of ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biotechnology company, from January 2011 to October 2018, and as a member of the board of directors of Clinical Data, Inc. (previously traded on Nasdaq prior to its acquisition by Forest Laboratories, Inc. in April 2011) from September 2002 to April 2011, and was Chairman of the board of directors from December 2004 to April 2011.

Mr. Kirk served on the board of visitors of Radford University from July 2003 to June 2009, was Rector of the board of directors from September 2006 to September 2008 and served on the board of directors of the Radford University Foundation, Inc. from September 1998 to May 2011. He served on the board of visitors of the University of Virginia and Affiliated Schools from July 2009 to October 2012, on the Virginia Advisory Council on Revenue Estimates from July 2006 to October 2012 and on the Governor’s Economic Development and Jobs Creation Commission from April 2010 to October 2012. Mr. Kirk received a BA in Business from Radford University and a JD from the University of Virginia.

What is Randal J. Kirk's net worth?

The estimated net worth of Randal J. Kirk is at least $989,868.78 as of December 28th, 2023. Mr. Kirk owns 1,096,686 shares of Precigen stock worth more than $989,869 as of November 23rd. This net worth evaluation does not reflect any other assets that Mr. Kirk may own. Additionally, Mr. Kirk receives a salary of $100,000.00 as Director at Precigen. Learn More about Randal J. Kirk's net worth.

How old is Randal J. Kirk?

Mr. Kirk is currently 71 years old. There are 6 older executives and no younger executives at Precigen. Learn More on Randal J. Kirk's age.

What is Randal J. Kirk's salary?

As the Director of Precigen, Inc., Mr. Kirk earns $100,000.00 per year. There are 5 executives that earn more than Mr. Kirk. The highest earning executive at Precigen is Dr. Helen Sabzevari MPH, Ph.D., President, CEO & Director, who commands a salary of $1,020,000.00 per year. Learn More on Randal J. Kirk's salary.

How do I contact Randal J. Kirk?

The corporate mailing address for Mr. Kirk and other Precigen executives is 20374 Seneca Meadows Parkway, Germantown MD, 20876. Precigen can also be reached via phone at (301) 556-9900 and via email at [email protected]. Learn More on Randal J. Kirk's contact information.

Has Randal J. Kirk been buying or selling shares of Precigen?

Randal J. Kirk has not been actively trading shares of Precigen over the course of the past ninety days. Most recently, on Thursday, December 28th, Randal J. Kirk bought 96,686 shares of Precigen stock. The stock was acquired at an average cost of $1.41 per share, with a total value of $136,327.26. Following the completion of the transaction, the director now directly owns 1,096,686 shares of the company's stock, valued at $1,546,327.26. Learn More on Randal J. Kirk's trading history.

Who are Precigen's active insiders?

Precigen's insider roster includes Randal Kirk (Director), Donald Lehr (Insider), David Obstler (CFO), Jeffrey Perez (SVP), Helen Sabzevari (CEO), and Harry Thomasian, Jr. (CFO). Learn More on Precigen's active insiders.

Are insiders buying or selling shares of Precigen?

In the last year, Precigen insiders bought shares 2 times. They purchased a total of 155,509 shares worth more than $186,326.81. The most recent insider tranaction occured on August, 9th when SVP Jeffrey Thomas Perez bought 58,823 shares worth more than $49,999.55. Insiders at Precigen own 44.9% of the company. Learn More about insider trades at Precigen.

Information on this page was last updated on 8/9/2024.

Randal J. Kirk Insider Trading History at Precigen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/28/2023Buy96,686$1.41$136,327.261,096,686View SEC Filing Icon  
8/16/2023Buy119,411$1.51$180,310.6131,837,786View SEC Filing Icon  
1/27/2023Buy11,428,571$1.75$19,999,999.2531,129,164View SEC Filing Icon  
11/22/2021Buy206,004$3.59$739,554.36View SEC Filing Icon  
11/19/2021Buy307,661$3.75$1,153,728.75View SEC Filing Icon  
8/11/2020Buy808,518$4.50$3,638,331.00View SEC Filing Icon  
3/20/2020Buy1,000,000$2.95$2,950,000.00
1/31/2020Buy5,972,696$5.86$34,999,998.56View SEC Filing Icon  
6/7/2019Buy483,268$5.24$2,532,324.32View SEC Filing Icon  
6/4/2019Buy203,321$4.91$998,306.11View SEC Filing Icon  
5/30/2019Buy330,180$4.75$1,568,355.00View SEC Filing Icon  
5/24/2019Buy273,367$4.69$1,282,091.23View SEC Filing Icon  
5/22/2019Buy115,187$4.70$541,378.90View SEC Filing Icon  
5/20/2019Buy301,670$4.63$1,396,732.10View SEC Filing Icon  
5/17/2019Buy60,530$4.69$283,885.70View SEC Filing Icon  
5/15/2019Buy1,257,727$4.40$5,533,998.80View SEC Filing Icon  
5/13/2019Buy376,932$4.25$1,601,961.00View SEC Filing Icon  
4/3/2019Sell95,241$0.65$61,906.65View SEC Filing Icon  
4/1/2019Sell41,678$0.67$27,924.26View SEC Filing Icon  
7/3/2018Buy7,479,431$13.37$99,999,992.47View SEC Filing Icon  
1/19/2018Buy1,000,000$12.50$12,500,000.00View SEC Filing Icon  
8/11/2017Buy132,625$18.85$2,499,981.25View SEC Filing Icon  
12/13/2016Buy34,606$28.90$1,000,113.40View SEC Filing Icon  
5/13/2016Buy41,830$23.92$1,000,573.60View SEC Filing Icon  
12/11/2015Buy124,475$29.85$3,715,578.75View SEC Filing Icon  
12/7/2015Buy237,525$30.69$7,289,642.25View SEC Filing Icon  
1/27/2015Buy555,556$27.00$15,000,012.00View SEC Filing Icon  
8/13/2013Buy1,887,500$16.00$30,200,000.00View SEC Filing Icon  
See Full Table

Randal J. Kirk Buying and Selling Activity at Precigen

This chart shows Randal J Kirk's buying and selling at Precigen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Precigen Company Overview

Precigen logo
Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Read More

Today's Range

Now: $0.90
Low: $0.89
High: $0.97

50 Day Range

MA: $0.91
Low: $0.79
High: $1.07

2 Week Range

Now: $0.90
Low: $0.77
High: $1.93

Volume

846,951 shs

Average Volume

871,444 shs

Market Capitalization

$264.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.68